Arana completes Phase II
Monday, 09 March, 2009
Arana Therapeutics, currently the subject of a takeover bid by US company Cephalon, has completed its Phase II trial of lead candidate ART621 in psoriasis.
The trial met the primary endpoints of tolerability and safety. Secondary findings included evidence of anti-tumour necrosis factor activity, a reduction in severity in some patients and no antibody responses against the drug, suggesting the drug has low immunogenicity, the company said.
ART621 is a human domain-based antibody directed against TNF. It is currently in two Phase II trials for rheumatoid arthritis in combination with methotrexate.
The study was conducted at the Nucleus Network in Melbourne and CMAX in Adelaide.
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
